What Happened?

Shares of life sciences company Revvity (NYSE: RVTY) fell 5.1% in the afternoon session after several analyst firms lowered their price targets on the stock, pushing shares to a 52-week low. The negative sentiment comes despite a recent second-quarter earnings report where Revvity surpassed analyst expectations for both revenue and earnings per share. However, firms including Stifel, Raymond James, and Jefferies cut their price targets. Analysts cited ongoing challenges in China, including pressures from the ImmunoDx market, reimbursement difficulties, and the impact of drug-related group policies on the company's financial outlook. The stock's fall to a new 52-week low of $85.01 reflects investor concerns that these specific market headwinds are outweighing the recent positive earnings results.

The stock market overreacts to news, and big price drops can present good opportunities to buy high-quality stocks. Is now the time to buy Revvity? Access our full analysis report here, it’s free.

What Is The Market Telling Us

Revvity’s shares are somewhat volatile and have had 10 moves greater than 5% over the last year. In that context, today’s move indicates the market considers this news meaningful but not something that would fundamentally change its perception of the business.

The previous big move we wrote about was about 22 hours ago when the stock dropped 3.1% on the news that the major indices continued to retreat (Nasdaq -1.5%, S&P 500 -1.2%) amid profit-taking and renewed concerns about tariffs. Investor sentiment was soured by a report indicating that U.S. manufacturing activity contracted for the sixth consecutive month, a sign of economic weakness that was not well-received. 

Adding to the pressure, the 10-year Treasury yield climbed, which tends to make stocks less attractive to investors by offering a safer return on bonds. This combination of negative economic data and pressure from the bond market led to a widespread downturn across Wall Street, pulling down individual stocks like Revvity in the process.

Revvity is down 25.3% since the beginning of the year, and at $83.72 per share, it is trading 34.5% below its 52-week high of $127.75 from September 2024. Investors who bought $1,000 worth of Revvity’s shares 5 years ago would now be looking at an investment worth $721.43.

Do you want to know what moves the business you care about? Add them to your StockStory watchlist and every time a stock significantly moves, we provide you with a timely explanation straight to your inbox. It’s free and will only take you a second.